What's Happening?
Clinilabs, a specialty contract research organization focused on central nervous system drug and device development, has announced a leadership expansion. Laura Shannon has been appointed as the new Chief Executive Officer, while the company's founder,
Gary Zammit, Ph.D., transitions to the role of Executive Chairperson. Shannon brings over 30 years of experience in the biopharma industry, having previously served as EVP and Chief Commercial Officer at IQVIA. Her appointment is part of Clinilabs' strategy to enhance its global capabilities and commitment to advancing treatments for psychiatric and neurological disorders.
Why It's Important?
The leadership change at Clinilabs is crucial as it positions the company for further growth and innovation in the CNS drug and device development sector. With Shannon's extensive experience, Clinilabs aims to strengthen its global presence and enhance its research capabilities. This move reflects the broader trend in the biopharma industry towards strategic leadership appointments to drive innovation and address complex healthcare challenges. The expansion is expected to benefit patients with neurological disorders by accelerating the development of effective treatments.
